ClinicalTrials.gg
CompletedNCT03387150Updated Apr 5, 2023Results posted

Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults

A Phase 1 interventional study of VRC07-523LS and Placebo in HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 7 sites in 2 countries. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-05.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID) — 10 open to participants now, 15 under way, 1 of them phase 3. HIV Infections · National Institute of Allergy and Infectious Diseases (NIAID).

Enrollment
266th of 883
124 · median 59
Started
2018
with 10 others
Phase 1
365 of 1,034
4 open now
Registered
983rd of 1,034
by date

Among the 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 266th largest by enrollment of the 883 interventional ones that give a count, is one of 11 that started in 2018, is one of 365 in phase 1, and was the 983rd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

10 of the 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and serum concentrations of a human monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), administered in multiple doses and routes to healthy, HIV-uninfected adults.

Read the detailed description

This study will evaluate the safety, tolerability, and serum concentrations of a human monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), administered in multiple doses and routes to healthy, HIV-uninfected adults.

Participants will be randomly assigned to one of six groups. Participants in Group 1 will receive 2.5 mg/kg of VRC07-523LS by intravenous (IV) infusion at Weeks 0, 16, 32, 48, and 64. Participants in Group 2 will receive 5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64. Participants in Group 3 will receive 20 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64. Participants in Group 4 will receive 2.5 mg/kg of VRC07-523LS by subcutaneous (SC) injection at Weeks 0, 16, 32, 48, and 64. Participants in Group 5 will receive 5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64. Participants in Group 6 will receive 2.5 mg/kg of VRC07-523LS or placebo by intramuscular (IM) injection at Weeks 0, 16, 32, 48, and 64.

Participants will attend numerous study visits throughout the course of the study, beginning at Week 0 through Week 112. Visits may include physical examinations, blood and urine collection, HIV testing, risk reduction counseling, and questionnaires.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General and Demographic Criteria

  • Age of 18 to 50 years
  • Access to a participating clinical research site (CRS) and willingness to be followed for the planned duration of the study
  • Ability and willingness to provide
  • Assessment of understanding: volunteer demonstrates understanding of this study and completes a questionnaire prior to first study product administration with verbal demonstration of understanding of all questionnaire items answered incorrectly
  • Agrees not to enroll in another study of an research agent until completion of the last required protocol clinic visit
  • Good general health as shown by medical history, physical exam, and screening laboratory tests

-Related Criteria:

  • Willingness to receive HIV test results
  • Willingness to discuss HIV infection risks and amenable to HIV risk reduction counseling.
  • Assessed by the clinic staff as being at 'low risk' for HIV infection and committed to maintaining behavior consistent with those criteria through the last required protocol clinic visit (see the protocol for more information).

Laboratory Inclusion Values

Hemogram/Complete Blood Count (CBC)

  • greater than or equal to 11.0 g/dL for volunteers who were assigned female sex at birth, greater than or equal to 13.0 g/dL for volunteers who were assigned male sex at birth. For transgender participants who have been on hormone therapy for more than 6 consecutive months, determine hemoglobin eligibility based on the gender with which they identify (ie, a transgender female who has been on hormone therapy for more than 6 consecutive months should be assessed for eligibility using the hemoglobin parameters for volunteers assigned female sex at birth).
  • White blood cell (WBC) count equal to 2,500 to 12,000 cells/mm\^3
  • WBC differential either within institutional normal range or with site physician approval
  • equal to 125,000 to 550,000/mm\^3

Chemistry

  • Chemistry panel: (ALT) less than 1.25 times the institutional and creatinine less than or equal to institutional upper limits of normal.

Virology

  • Negative HIV-1 and -2 blood test: US volunteers must have a negative US Food and Drug Administration (FDA)-approved enzyme immunoassay (EIA) or chemiluminescent microparticle immunoassay (CMIA). Non-US sites may use locally available assays that have been approved by HVTN and HIV Prevention Trials Network (HPTN) Laboratory Operations.
  • Negative surface antigen (HBsAg)
  • Negative anti- virus antibodies (anti-HCV), or negative HCV polymerase chain reaction (PCR) if the anti-HCV is positive

Urine

  • Negative or trace urine protein

Reproductive Status

  • Volunteers who were assigned female sex at birth: negative serum or urine beta human chorionic gonadotropin (β-HCG) pregnancy test performed prior to study product administration on the day of initial study infusion/injection. Persons who are NOT of due to having undergone total hysterectomy or bilateral oophorectomy (verified by medical records), are not required to undergo pregnancy testing.
  • Reproductive status: A volunteer who was assigned female sex at birth must:

    • Agree to use effective (see protocol for more information) for sexual activity that could lead to pregnancy from at least 21 days prior to enrollment through the last required protocol clinic visit. Effective contraception is defined as using the following methods:
    • Condoms (male or female) with or without a spermicide,
    • Diaphragm or cervical cap with spermicide,
    • Intrauterine device (IUD),
    • Hormonal contraception, or
    • Any other contraceptive method approved by the HVTN 127/HPTN 087 Protocol Safety Review Team (PSRT)
    • Successful vasectomy in any partner assigned male sex at birth (considered successful if a volunteer reports that a partner assigned male sex at birth has [1] documentation of azoospermia by microscopy, or [2] a vasectomy more than 2 years ago with no resultant pregnancy despite sexual activity postvasectomy);
    • Or not be of reproductive potential, such as having reached menopause (no menses for 1 year) or having undergone hysterectomy, bilateral oophorectomy, or tubal ligation;
    • Or plan to be sexually abstinent until at least 6 months following the last study product administration.
  • Volunteers who were assigned female sex at birth must also agree not to seek pregnancy through alternative methods, such as artificial insemination or in vitro fertilization until after the last required protocol clinic visit

Exclusion criteria

Exclusion Criteria:

General

  • Weight greater than 115 kg
  • Blood products received within 120 days before first study product administration, unless eligibility for earlier enrollment is determined by the HVTN 127/HPTN 087 PSRT
  • research agents received within 30 days before first study product administration
  • Intent to participate in another study of an investigational research agent or any other study that requires non-Network antibody testing during the planned duration of the HVTN 127/HPTN 087 study
  • Pregnant or breastfeeding

Vaccines and other Injections

  • HIV vaccine(s) received in a prior HIV vaccine trial. For volunteers who have received control/placebo in an HIV vaccine trial, the HVTN 127/HPTN 087 PSRT will determine eligibility on a case-by-case basis.
  • Previous receipt of humanized or human mAbs, whether licensed or investigational; the HVTN 127/HPTN 087 PSRT will determine eligibility on a case-by-case basis.
  • Previous receipt of monoclonal antibodies VRC01, VRC01LS, or VRC07-523LS

Immune System

  • medications received within 30 days before first injection or infusion (Not exclusionary: [1] nasal spray; [2] inhaled corticosteroids; [3] topical corticosteroids for mild, uncomplicated dermatitis; or [4] a single course of oral/parenteral prednisone or equivalent at doses less than 2 mg/kg/day and length of therapy less than 11 days with completion at least 30 days prior to enrollment)
  • Serious adverse reactions to VRC07-523LS formulation components, including history of anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain
  • Immunoglobulin received within 90 days before first injection or infusion, unless eligibility for earlier enrollment is determined by the HVTN 127/HPTN 087 PSRT
  • disease (Not excluded from participation: Volunteer with mild, stable and uncomplicated autoimmune disease that does not require immunosuppressive medication and that, in the judgment of the site investigator, is likely not subject to exacerbation and likely not to complicate Solicited and Unsolicited adverse event (AE) assessments)
  • Immunodeficiency

medical conditions

  • Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to:

    • A process that would affect the immune response,
    • A process that would require medication that affects the immune response,
    • Any to repeated injections, infusions, or blood draws, including inability to establish venous access,
    • A condition that requires active medical intervention or monitoring to avert grave danger to the volunteer's health or well-being during the study period,
    • A condition or process (eg, chronic urticaria or recent injection or infusion with evidence of residual inflammation) for which signs or symptoms could be confused with reactions to the study product, or
    • Any condition specifically listed among the exclusion criteria.
  • Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or Solicited AEs, or a volunteer's ability to give
  • Psychiatric condition that precludes compliance with the protocol. Specifically excluded are persons with psychoses within the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years.
  • Current anti-tuberculosis (TB) therapy
  • Asthma other than mild or moderate, well-controlled asthma. (Symptoms of asthma severity as defined in the most recent National Asthma Education and Prevention Program (NAEPP) Expert Panel report). Exclude a volunteer who:

    • Uses a short-acting rescue inhaler (typically a beta 2 agonist) daily, or
    • Uses high dose inhaled corticosteroids, or
    • In the past year has had either of the following:
    • Greater than 1 exacerbation of symptoms treated with oral/parenteral corticosteroids;
    • Needed emergency care, urgent care, hospitalization, or intubation for asthma.
  • Diabetes mellitus type 1 or type 2 (Not excluded: type 2 cases controlled with diet alone or a history of isolated gestational diabetes.)
  • Hypertension:

    • If a person has been found to have elevated blood pressure or hypertension during screening or previously, exclude for blood pressure that is not well controlled. Well-controlled blood pressure is defined as consistently less than or equal to 140 mm Hg systolic and less than or equal to 90 mm Hg diastolic, with or without medication, with only isolated, brief instances of higher readings, which must be less than or equal to 150 mm Hg systolic and less than or equal to 100 mm Hg diastolic. For these volunteers, blood pressure must be less than or equal to 140 mm Hg systolic and less than or equal to 90 mm Hg diastolic at enrollment.
    • If a person has NOT been found to have elevated blood pressure or hypertension during screening or previously, exclude for systolic blood pressure greater than or equal to 150 mm Hg at enrollment or diastolic blood pressure greater than or equal to 100 mm Hg at enrollment.
  • Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or disorder requiring special precautions)
  • (Not excluded from participation: Volunteer who has had malignancy excised surgically and who, in the investigator's estimation, has a reasonable assurance of sustained cure, or who is unlikely to experience recurrence of malignancy during the period of the study)
  • Seizure disorder: History of seizure(s) within past three years. Also exclude if volunteer has used medications in order to prevent or treat seizure(s) at any time within the past 3 years.
  • Asplenia: any condition resulting in the absence of a functional spleen
  • History of hereditary angioedema, acquired angioedema, or idiopathic angioedema
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Group 1: VRC07-523LS

    Participants in Group 1 will receive 2.5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.

    Biological: VRC07-523LS

  • Experimental
    Group 2: VRC07-523LS

    Participants in Group 2 will receive 5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.

    Biological: VRC07-523LS

  • Experimental
    Group 3: VRC07-523LS

    Participants in Group 3 will receive 20 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.

    Biological: VRC07-523LS

  • Experimental
    Group 4: VRC07-523LS

    Participants in Group 4 will receive 2.5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.

    Biological: VRC07-523LS

  • Experimental
    Group 5: VRC07-523LS

    Participants in Group 5 will receive 5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.

    Biological: VRC07-523LS

  • Experimental
    Group T6 VRC07-523LS

    Participants in Group T6 will receive 2.5 mg/kg of VRC07-523LS by IM injection at Weeks 0, 16, 32, 48, and 64.

    Biological: VRC07-523LS

  • Placebo comparator
    Group P6: Placebo

    Participants in Group P6 will receive 2.5 mg/kg of placebo by IM injection at Weeks 0, 16, 32, 48, and 64.

    Biological: Placebo

Interventions

  • BiologicalVRC07-523LS

    Administered by intravenous (IV) infusion, subcutaneous (SC) injection, or intramuscular (IM) injection, depending on which group participants are in

    Also known as: VRC-HIVMAB075-00-AB

  • BiologicalPlacebo

    Sodium Chloride for Injection USP, 0.9%; administered by IM injection

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness

    Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented

    Time frame: Measured through 3 days after each vaccine dose at Weeks 0, 16, 32, 48, 64

  2. Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration

    Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented

    Time frame: Measured through 3 days after each vaccine dose at Weeks 0, 16, 32, 48, 64

  3. Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms

    Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The following symptoms are considered as systemic reactogenicity if the onset date was within the periods of assessment specified in the protocol: malaise and/or fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and body temperature. The item Max. Systemic Symptoms is the maximum of the individual systemic reactogenicities excluding body temperature for a participant.

    Time frame: Measured through 3 days after each vaccine dose at Weeks 0, 16, 32, 48, 64

  4. Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT)

    For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.

    Time frame: Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728

  5. Chemistry and Hematology Laboratory Measures - Creatinine

    For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.

    Time frame: Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728

  6. Chemistry and Hematology Laboratory Measures - Hemoglobin

    For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.

    Time frame: Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728

  7. Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count

    For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.

    Time frame: Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728

  8. Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC)

    For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.

    Time frame: Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728

  9. Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC).

    The number (percentage) of participants with lab grade \>= 1 for alanine aminotransferase (ALT), creatinine, hemoglobin, lymphocyte count, neutrophil count, platelets, white blood cells (WBC) was summarized by arm

    Time frame: Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728

  10. VRC07523LS Serum Concentrations

    VRC07523LS serum concentrations measured in healthy human subjects after up to five administrations of the study product via the IV, SC or IM routes at various doses. Serum concentrations between the first and second study product administrations (Target Visit Day 0-112) were measured using ELISA assay in all enrolled participants. Serum concentrations after the second study product administrations (Target Visit Day 168-784) were measured using BAMA (LUMINEX) assay in a subset of participants enrolled in each treatment group and all particiants in plocebo group. serum concentrations below the lower limit of quantification (LLoQ) were replaced by half the LLoQ. Thus, concentrations below the LLoQ when measured by the ELISA assay were replaced by 0.5 ug/ml and concentrations below the LLoQ when measured by the BAMA assay were replaced by 0.02285 ug/ml.

    Time frame: Target Visit Days 0, 3, 6, 28, 56, 84, 112, 168, 224, 280, 336, 392, 448, 504, 560, 616, 672, 728, 784 (i.e., visit numbers 2 through 20)

Secondary outcomes

  1. Occurrence of Antidrug Antibodies (ADA)

    Antidrug antibodies (ADA) are most typically detected and characterized using a tiered testing strategy. In Tier I, a sensitive binding assay is used to determine if samples may have ADA present. In Tier II, the response is confirmed, typically by establishing the specificity of the response by competition with free drug. In Tier III, the response is characterized, typically with a neutralization reduction assay and/or a titering assay.

    Time frame: Day 0, 6, 112, 224, 448

  2. Magnitude and Breadth of Neutralizing Antibody Responses Against Autologous Viral Isolates as Assessed by Area Under the Magnitude-breadth Curves 8, 72, 88 Weeks After the First Study Product Administration.

    Magnitude-breadth characterize the magnitude (ID50 or ID80 titers) and breadth (number of virus isolates) of each individual serum sample assayed against a panel of virus isolates. MB curves show, for each possible magnitude threshold, the fraction of assays with magnitudes greater than this threshold. The area under the magnitude-breadth curve (AUC-MB) is calculated as the average of the log10-based ID50 or ID80 titers over the panel of isolates. Isolates includes: H703_0646_051sN, H703_1471_190s, H703_1750_140Es, H704_0726_080sN, H704_1535_030sN, H704_2544_140eN01, PVO.4.

    Time frame: Weeks 8, 72, and 88 following the first study product administration

07

Results

Posted Mar 21, 2022

Participant flow

Participant flow — Overall Study
MilestoneGroup 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: Placebo
Started1919212120213
Safety population1919212120213
Completed1316161414143
Not completed6357670
Withdrew: Withdrawal by subject3034120
Withdrew: Lost to follow-up3223330
Withdrew: Participant unable to adhere to visit0100220

Outcome measures

PrimaryNumber of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness

Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented

Time frame:
Measured through 3 days after each vaccine dose at Weeks 0, 16, 32, 48, 64
Reported as:
Count of participants · Participants
Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness
ParticipantsGroup 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: Placebo
None1211158572
Mild6851115131
Moderate1012010
Severe0000000
Potentially Life-threatening0000000
PrimaryNumber of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration

Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented

Time frame:
Measured through 3 days after each vaccine dose at Weeks 0, 16, 32, 48, 64
Reported as:
Count of participants · Participants
Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration
ParticipantsGroup 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: Placebo
Erythema/Redness — None14151677193
Erythema/Redness — Not gradable3432300
Erythema/Redness — Gr 1: 2.5 - less than 5cm dim.0012200
Erythema/Redness — Gr 1: 6.25 - less than 25cm^2 area1004320
Erythema/Redness — Gr 2: 5 - less than 10cm dim.0012500
Erythema/Redness — Gr 2: 25 - less than 100cm^2 area1001000
Erythema/Redness — Gr 3: >= 10cm dim.0001000
Erythema/Redness — Gr 3: >= 100cm^2 area0002000
Erythema/Redness — Gr 3: complications AE0000000
Erythema/Redness — Gr 4: complications AE0000000
Erythema/Redness — Missing0000000
Induration/Swelling — None1916201212183
Induration/Swelling — Not gradable0312620
Induration/Swelling — Gr 1: 2.5 - less than 5cm dim.0004000
Induration/Swelling — Gr 1: 6.25 - less than 25cm^2 area0001010
Induration/Swelling — Gr 2: 5 - less than 10cm dim.0000100
Induration/Swelling — Gr 2: 25 - less than 100cm^2 area0001100
Induration/Swelling — Gr 3: >= 10cm dim.0000000
Induration/Swelling — Gr 3: >= 100cm^2 area0001000
Induration/Swelling — Gr 3: complications AE0000000
Induration/Swelling — Gr 4: complications AE0000000
Induration/Swelling — Missing0000000
Erythema and/or Induration — None14151666173
Erythema and/or Induration — Not gradable3432420
Erythema and/or Induration — Gr 1: 2.5 - less than 5cm dim.0013200
Erythema and/or Induration — Gr 1: 6.25 - less than 25cm^2 area1004320
Erythema and/or Induration — Gr 2: 5 - less than 10cm dim.0012400
Erythema and/or Induration — Gr 2: 25 - less than 100cm^2 area1001100
Erythema and/or Induration — Gr 3: >= 10cm dim.0001000
Erythema and/or Induration — Gr 3: >= 100cm^2 area0002000
Erythema and/or Induration — Gr 3: complications AE0000000
Erythema and/or Induration — Gr 4: complications AE0000000
Erythema and/or Induration — Missing0000000
PrimaryNumber of Participants Reporting Systemic Reactogenicity Signs and Symptoms

Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The following symptoms are considered as systemic reactogenicity if the onset date was within the periods of assessment specified in the protocol: malaise and/or fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and body temperature. The item Max. Systemic Symptoms is the maximum of the individual systemic reactogenicities excluding body temperature for a participant.

Time frame:
Measured through 3 days after each vaccine dose at Weeks 0, 16, 32, 48, 64
Reported as:
Count of participants · Participants
Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms
ParticipantsGroup 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: Placebo
Malaise and/or fatigue — None101071213141
Malaise and/or fatigue — Mild6576642
Malaise and/or fatigue — Moderate3453130
Malaise and/or fatigue — Severe0020000
Malaise and/or fatigue — Potentially Life-threatening0000000
Myalgia — None1816141817173
Myalgia — Mild1322340
Myalgia — Moderate0041000
Myalgia — Severe0010000
Myalgia — Potentially Life-threatening0000000
Headache — None131141216132
Headache — Mild46126471
Headache — Moderate2253010
Headache — Severe0000000
Headache — Potentially Life-threatening0000000
Nausea — None1515171618182
Nausea — Mild4215131
Nausea — Moderate0230100
Nausea — Severe0000000
Nausea — Potentially Life-threatening0000000
Chills — None1917132018202
Chills — Mild0151211
Chills — Moderate0130000
Chills — Severe0000000
Chills — Potentially Life-threatening0000000
Arthralgia — None1916141919193
Arthralgia — Mild0341120
Arthralgia — Moderate0021000
Arthralgia — Severe0010000
Arthralgia — Potentially Life-threatening0000000
Facial flushing — None1918171919193
Facial flushing — Mild0142120
Facial flushing — Moderate0000000
Facial flushing — Severe0000000
Facial flushing — Potentially Life-threatening0000000
Non-exertional dyspnea — None1918192119213
Non-exertional dyspnea — Mild0120100
Non-exertional dyspnea — Moderate0000000
Non-exertional dyspnea — Severe0000000
Non-exertional dyspnea — Potentially Life-threatening0000000
Non-exertional tachycardia — None1919212120213
Non-exertional tachycardia — Mild0000000
Non-exertional tachycardia — Moderate0000000
Non-exertional tachycardia — Severe0000000
Non-exertional tachycardia — Potentially Life-threatening0000000
Unexplained diaphoresis — None1919192019213
Unexplained diaphoresis — Mild0021100
Unexplained diaphoresis — Moderate0000000
Unexplained diaphoresis — Severe0000000
Unexplained diaphoresis — Potentially Life-threatening0000000
Generalized Pruritus — None1919212119213
Generalized Pruritus — Mild0000100
Generalized Pruritus — Moderate0000000
Generalized Pruritus — Severe0000000
Generalized Pruritus — Potentially Life-threatening0000000
Urticaria — None1919212120213
Urticaria — Mild0000000
Urticaria — Moderate0000000
Urticaria — Severe0000000
Urticaria — Potentially Life-threatening0000000
Max. Systemic Symptoms — None854101181
Max. Systemic Symptoms — Mild79858102
Max. Systemic Symptoms — Moderate4576130
Max. Systemic Symptoms — Severe0020000
Max. Systemic Symptoms — Potentially Life-threatening0000000
Temperature — None1718182120203
Temperature — Mild2130000
Temperature — Moderate0000010
Temperature — Severe0000000
Temperature — Potentially Life-threatening0000000
PrimaryChemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT)

For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.

Time frame:
Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728
Reported as:
Median · U/L
Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT)
U/LGroup 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: Placebo
ALT (SGPT) (U/L)- Screening16 (11 to 21)16 (13 to 21)16 (12 to 21)14 (12 to 17)18 (10.5 to 20)13 (13 to 20)13 (12 to 16)
ALT (SGPT) (U/L)- 0/Enrollment14 (9 to 17)16 (12 to 17)19 (12 to 22)13.5 (10 to 21)13 (11.5 to 21.5)12 (10 to 20)17 (15 to 33)
ALT (SGPT) (U/L)- 5615 (10 to 23)16 (12 to 21)15 (12.5 to 23)13 (10 to 21)15 (11 to 24)13 (11 to 23)31 (13 to 114)
ALT (SGPT) (U/L)- 11216 (11 to 18)20 (13 to 23)13 (11.5 to 20.5)12 (12 to 18)16 (14 to 25)14 (10.5 to 20.5)19 (16 to 42)
ALT (SGPT) (U/L)- 16813.5 (11 to 21)14.5 (13 to 23)15 (10 to 21)14 (10 to 24.5)16.5 (14 to 28)15 (12 to 23)19 (13 to 38)
ALT (SGPT) (U/L)- 22418 (10.5 to 22.5)17 (13 to 21)15.5 (11.5 to 19.5)13 (11 to 25)14 (12 to 20)14.5 (12.5 to 19)17 (13 to 39)
ALT (SGPT) (U/L)- 28016 (10 to 29)18 (14 to 25)15 (13 to 20)15 (11 to 23)17 (11 to 22)14 (11 to 23)18 (14 to 22)
ALT (SGPT) (U/L)- 33615 (11 to 23)17 (15 to 18)14.5 (11 to 22)15 (11 to 20)16 (11.5 to 20)15 (13 to 18)13 (11 to 41)
ALT (SGPT) (U/L)- 39217 (10 to 34)16 (12 to 21)19 (11 to 23)15 (10 to 24)16 (14 to 28)15 (12 to 17)18 (14 to 39)
ALT (SGPT) (U/L)- 44813 (11 to 20)16.5 (13.5 to 20.5)17.5 (13 to 19.5)16 (10 to 22)18 (11 to 32)13 (11 to 18)16 (14 to 38)
ALT (SGPT) (U/L)- 50412 (9 to 16)15 (12.5 to 31)13.5 (11 to 16.5)14.5 (10 to 22)16.5 (10 to 20.5)17 (12 to 21)15 (11 to 53)
ALT (SGPT) (U/L)- 72819 (19 to 19)16 (15 to 26)16 (13 to 28.5)18.5 (15 to 20)18 (12.5 to 25)14 (9 to 26)26 (26 to 26)
PrimaryChemistry and Hematology Laboratory Measures - Creatinine

For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.

Time frame:
Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728
Reported as:
Median · mg/dL
Chemistry and Hematology Laboratory Measures - Creatinine
mg/dLGroup 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: Placebo
Creatinine (mg/dL)- Screening0.85 (0.69 to 1)0.92 (0.78 to 1)0.84 (0.76 to 0.96)0.79 (0.7 to 0.9)0.84 (0.77 to 0.91)0.86 (0.72 to 0.98)0.74 (0.66 to 0.78)
Creatinine (mg/dL)- 0/Enrollment0.8 (0.76 to 1.05)0.93 (0.81 to 1)0.83 (0.72 to 0.93)0.83 (0.78 to 1.02)0.8 (0.65 to 0.9)0.83 (0.71 to 0.93)0.77 (0.64 to 0.81)
Creatinine (mg/dL)- 560.84 (0.7 to 1)0.9 (0.8 to 0.98)0.94 (0.75 to 1.02)0.82 (0.74 to 0.91)0.82 (0.68 to 1)0.8 (0.74 to 0.97)0.7 (0.66 to 0.74)
Creatinine (mg/dL)- 1120.8 (0.69 to 0.89)0.88 (0.79 to 0.94)0.88 (0.71 to 1.02)0.86 (0.76 to 0.93)0.79 (0.7 to 0.96)0.84 (0.74 to 0.96)0.72 (0.64 to 0.75)
Creatinine (mg/dL)- 1680.86 (0.75 to 0.92)0.91 (0.8 to 1)0.81 (0.73 to 0.93)0.83 (0.77 to 1)0.81 (0.7 to 0.95)0.9 (0.75 to 1)0.7 (0.68 to 0.79)
Creatinine (mg/dL)- 2240.79 (0.69 to 0.9)0.86 (0.72 to 0.99)0.81 (0.72 to 0.95)0.81 (0.77 to 0.89)0.83 (0.67 to 0.94)0.82 (0.73 to 0.97)0.72 (0.68 to 0.8)
Creatinine (mg/dL)- 2800.81 (0.71 to 0.88)0.89 (0.77 to 1.07)0.78 (0.72 to 0.95)0.81 (0.76 to 0.95)0.85 (0.7 to 0.9)0.89 (0.73 to 0.96)0.72 (0.7 to 0.74)
Creatinine (mg/dL)- 3360.84 (0.69 to 0.9)0.85 (0.76 to 0.99)0.85 (0.72 to 0.93)0.84 (0.77 to 0.95)0.87 (0.77 to 1.01)0.87 (0.77 to 0.99)0.78 (0.7 to 0.89)
Creatinine (mg/dL)- 3920.88 (0.7 to 0.9)0.95 (0.8 to 1.02)0.82 (0.8 to 0.96)0.85 (0.72 to 0.96)0.89 (0.76 to 1)0.89 (0.8 to 1)0.75 (0.71 to 0.9)
Creatinine (mg/dL)- 4480.82 (0.76 to 0.91)0.9 (0.81 to 1)0.8 (0.72 to 0.91)0.81 (0.74 to 0.96)0.9 (0.74 to 0.97)0.84 (0.75 to 0.97)0.75 (0.7 to 0.76)
Creatinine (mg/dL)- 5040.87 (0.76 to 1.06)0.92 (0.78 to 1.08)0.78 (0.71 to 0.98)0.85 (0.78 to 0.95)0.8 (0.72 to 0.86)0.88 (0.7 to 0.99)0.81 (0.7 to 0.84)
Creatinine (mg/dL)- 7281.1 (1.1 to 1.1)1.1 (0.96 to 1.15)0.77 (0.68 to 0.92)0.87 (0.8 to 1.14)0.81 (0.77 to 0.86)0.89 (0.78 to 0.92)0.66 (0.66 to 0.66)
PrimaryChemistry and Hematology Laboratory Measures - Hemoglobin

For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.

Time frame:
Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728
Reported as:
Median · g/dL
Chemistry and Hematology Laboratory Measures - Hemoglobin
g/dLGroup 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: Placebo
Hemoglobin (g/dL)- Screening13.3 (12.7 to 14)14.2 (13.5 to 15.3)13.8 (13.3 to 14.8)13.1 (12.7 to 14.1)13.8 (13.15 to 15.1)14.4 (13 to 15.2)13.4 (12.1 to 14.1)
Hemoglobin (g/dL)- 0/Enrollment13.1 (12.3 to 14.2)13.9 (12.6 to 14.7)13.8 (12.8 to 14.5)13 (12.25 to 13.7)13.55 (13 to 15.2)14.1 (12.6 to 15)12.5 (11.7 to 13.4)
Hemoglobin (g/dL)- 5613.35 (12.7 to 13.8)14.25 (13.6 to 15.1)13.4 (12.45 to 14.85)12.9 (12.5 to 13.9)13.8 (12.8 to 14.6)14.4 (12 to 14.9)12.6 (12 to 13.1)
Hemoglobin (g/dL)- 11212.7 (11.9 to 13.9)13.95 (13.1 to 14.7)13.6 (12.55 to 15.15)13.1 (12.4 to 13.7)13.7 (12.6 to 14.6)14.45 (13.1 to 15.2)12.6 (12.2 to 14.1)
Hemoglobin (g/dL)- 16813.7 (12.65 to 14.75)14.1 (13 to 14.8)13.65 (13.1 to 15.5)13.25 (12.05 to 13.85)13.5 (13 to 14.7)14.5 (12.4 to 15.1)12.8 (12.3 to 13.8)
Hemoglobin (g/dL)- 22412.95 (12.3 to 13.8)13.7 (12.9 to 14.8)13.2 (12.5 to 14.95)13.5 (11.9 to 14.2)13.6 (13.3 to 14.7)14.15 (12.3 to 15)13.1 (11.8 to 13.3)
Hemoglobin (g/dL)- 28013.3 (12.6 to 14)13.7 (13.1 to 14.4)13.1 (12.9 to 14.7)13.3 (12.1 to 14.3)13.6 (12.9 to 14.6)14.2 (11.8 to 14.9)13.3 (12.2 to 14.4)
Hemoglobin (g/dL)- 33613.3 (12.5 to 14.4)13.6 (12.4 to 14.8)13.3 (12.3 to 15)13.3 (12.5 to 14.2)13.5 (12.75 to 15.2)14.2 (13.4 to 15.1)12.9 (12.2 to 13.5)
Hemoglobin (g/dL)- 39213.3 (12.4 to 14.2)14.2 (13.2 to 14.8)13.5 (12.6 to 15.3)13.4 (12.5 to 14.3)13.5 (13 to 14.7)14.3 (12.6 to 14.9)12.6 (12.6 to 14.9)
Hemoglobin (g/dL)- 44812.9 (12.5 to 13.5)13.95 (12.85 to 14.55)13.3 (12.2 to 14.4)13.3 (12.3 to 13.9)13.6 (12.7 to 14.8)14.2 (12.3 to 14.9)13 (11.9 to 13.7)
Hemoglobin (g/dL)- 50413.25 (12.3 to 14.05)14.35 (13.2 to 14.8)13.4 (12.6 to 13.9)13 (12.4 to 14.6)13.9 (12.85 to 14.75)14.4 (13.2 to 15.6)12.9 (12.1 to 14)
Hemoglobin (g/dL)- 72812.7 (12.7 to 12.7)14.7 (13.4 to 15)13.1 (12.45 to 14.55)14.9 (12.8 to 15.4)14.6 (13.65 to 15.5)14 (12.65 to 15.05)12.5 (12.5 to 12.5)
PrimaryChemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count

For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.

Time frame:
Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728
Reported as:
Median · 1000 cells /cubic mm
Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count
1000 cells /cubic mmGroup 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: Placebo
Neutrophils (1000/cubic mm)- Screening3.84 (2.6 to 5)3.7 (2.95 to 4.15)3.72 (2.8 to 4.19)3.24 (2.7 to 3.93)3.76 (2.77 to 5.19)2.82 (2.3 to 4.51)3.37 (3.3 to 7.32)
Neutrophils (1000/cubic mm)- 0/Enrollment2.95 (2.49 to 4.67)4.01 (3.16 to 4.73)3.92 (2.62 to 4.95)2.98 (2.3 to 3.97)3.31 (2.92 to 4.17)3.16 (2.42 to 3.94)5.82 (2.98 to 6.61)
Neutrophils (1000/cubic mm)- 563.12 (2.18 to 3.8)3.83 (3.02 to 4.94)4 (2.84 to 4.61)2.78 (2.4 to 4.06)3.47 (2.74 to 4.2)3.28 (2.27 to 4.07)7.27 (6.07 to 7.95)
Neutrophils (1000/cubic mm)- 1123.65 (3 to 4.07)3.87 (3.25 to 4.61)3.89 (2.8 to 5.28)3.03 (2.4 to 3.35)3.02 (2.62 to 3.61)3.17 (2.5 to 4.1)5.9 (4.9 to 6.6)
Neutrophils (1000/cubic mm)- 1683.35 (2.07 to 4.77)3.1 (2.66 to 3.87)3.61 (2.65 to 4.35)3.17 (2.68 to 4.42)3.19 (2.75 to 4.06)2.84 (2.4 to 4.2)6.19 (4.85 to 7.03)
Neutrophils (1000/cubic mm)- 2242.94 (1.95 to 3.82)3.55 (2.66 to 3.9)3.53 (2.73 to 4.29)2.89 (2.33 to 3.66)3.02 (2.44 to 3.7)2.75 (2.31 to 3.53)4.96 (4.85 to 6.87)
Neutrophils (1000/cubic mm)- 2802.69 (2.02 to 3.9)3.64 (2.7 to 4.72)3.57 (2.98 to 4.6)3.12 (2.5 to 4.06)3.15 (2.53 to 4.83)2.94 (2.21 to 3.72)5.27 (4.54 to 5.99)
Neutrophils (1000/cubic mm)- 3363.06 (2.2 to 4.69)3.55 (2.5 to 3.99)4.17 (3.14 to 4.52)3.04 (2.3 to 3.59)3.08 (2.33 to 3.66)2.83 (2.46 to 3.47)6.51 (5 to 7.58)
Neutrophils (1000/cubic mm)- 3923.13 (2.34 to 4.34)3.61 (2.86 to 4.26)3.69 (2.85 to 4.27)2.86 (2.51 to 3.5)3.53 (2.7 to 3.94)2.84 (2.42 to 3.75)6.13 (5.04 to 7.56)
Neutrophils (1000/cubic mm)- 4483.11 (2.34 to 4.16)3.76 (2.75 to 4.9)3.74 (3.14 to 5.09)3.05 (2.5 to 3.89)2.97 (2.18 to 4.47)3.04 (2.24 to 4.24)6.24 (5.09 to 6.46)
Neutrophils (1000/cubic mm)- 5043.38 (1.97 to 3.66)3.86 (2.8 to 4.59)3.91 (2.53 to 5.81)2.81 (2.39 to 3.44)3.39 (2.72 to 3.71)3.02 (2.1 to 3.65)6.42 (4.95 to 8.12)
Neutrophils (1000/cubic mm)- 7284.56 (4.56 to 4.56)4.25 (2.7 to 4.95)4.02 (3.25 to 5.21)2.3 (2.2 to 2.6)2.93 (2.45 to 3.78)3.63 (3.13 to 4.64)4.8 (4.8 to 4.8)
Lymphocytes (1000/cubic mm)- Screening2 (1.64 to 2.4)1.98 (1.7 to 2.44)2.04 (1.48 to 2.14)1.6 (1.4 to 2.07)1.92 (1.71 to 2.26)1.86 (1.66 to 2.67)3.06 (2.14 to 3.25)
Lymphocytes (1000/cubic mm)- 0/Enrollment1.86 (1.72 to 2.1)1.85 (1.6 to 2.25)1.87 (1.56 to 2.04)1.64 (1.44 to 2.21)1.86 (1.63 to 2.23)1.95 (1.55 to 2.29)2.94 (2.22 to 3.22)
Lymphocytes (1000/cubic mm)- 561.98 (1.57 to 2.25)1.94 (1.56 to 2.11)1.99 (1.33 to 2.5)1.86 (1.55 to 2)2.12 (1.78 to 2.48)1.87 (1.68 to 2.44)2.97 (2.05 to 3.38)
Lymphocytes (1000/cubic mm)- 1121.82 (1.59 to 2.07)1.8 (1.5 to 2.24)2.04 (1.55 to 2.46)1.77 (1.4 to 2.03)1.91 (1.76 to 2.16)1.93 (1.51 to 2.36)3.46 (2.34 to 3.55)
Lymphocytes (1000/cubic mm)- 1681.76 (1.53 to 1.99)1.8 (1.53 to 1.96)1.86 (1.53 to 2.07)1.61 (1.31 to 1.97)1.97 (1.65 to 2.26)1.89 (1.4 to 2.33)3.27 (2.17 to 3.33)
Lymphocytes (1000/cubic mm)- 2241.65 (1.44 to 2.12)1.91 (1.6 to 2.1)2.01 (1.68 to 2.51)1.61 (1.41 to 1.99)1.94 (1.68 to 2.23)1.74 (1.49 to 2.37)3.13 (1.91 to 3.85)
Lymphocytes (1000/cubic mm)- 2801.93 (1.75 to 2.13)1.71 (1.59 to 2.1)1.73 (1.3 to 2.32)1.7 (1.4 to 1.9)2.1 (1.81 to 2.66)1.92 (1.78 to 2.54)2.86 (2.15 to 3.58)
Lymphocytes (1000/cubic mm)- 3362 (1.62 to 2.06)1.69 (1.5 to 2.05)2.16 (1.63 to 3.01)1.76 (1.21 to 2.18)2.12 (1.81 to 2.41)1.82 (1.54 to 2.21)2.95 (1.79 to 3.82)
Lymphocytes (1000/cubic mm)- 3921.79 (1.53 to 2.08)1.8 (1.51 to 2.1)2.01 (1.43 to 2.85)1.58 (1.38 to 1.93)1.91 (1.7 to 2.3)1.82 (1.39 to 2.3)2.82 (1.46 to 3.1)
Lymphocytes (1000/cubic mm)- 4481.89 (1.68 to 2)1.83 (1.52 to 2.11)1.96 (1.34 to 2.44)1.8 (1.4 to 1.96)1.89 (1.63 to 2.39)1.99 (1.44 to 2.31)2.87 (1.94 to 3.52)
Lymphocytes (1000/cubic mm)- 5041.92 (1.54 to 2.28)1.89 (1.65 to 2.12)1.84 (1.5 to 2.26)1.79 (1.42 to 2.09)1.94 (1.85 to 2.29)1.76 (1.4 to 2.3)2.96 (1.3 to 3.02)
Lymphocytes (1000/cubic mm)- 7281.85 (1.85 to 1.85)1.7 (1.5 to 1.95)2.24 (1.79 to 3)1.5 (1.4 to 1.51)2.65 (1.95 to 3.45)1.69 (1.52 to 2.03)3.89 (3.89 to 3.89)
PrimaryChemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC)

For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.

Time frame:
Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728
Reported as:
Median · 1000 cells/cubic mm
Chemistry and Hematology Laboratory Measures - Platelets, White Blood Cells (WBC)
1000 cells/cubic mmGroup 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: Placebo
WBC (1000/cubic mm)- Screening6.4 (5 to 7.8)6.15 (5.36 to 7.44)6.8 (5.1 to 7.6)6.06 (4.54 to 6.59)6.7 (5.08 to 7.6)5.9 (4.71 to 8.5)7.1 (5.9 to 11.4)
WBC (1000/cubic mm)- 0/Enrollment6.2 (4.7 to 7.37)6.9 (5.4 to 7.7)6.51 (4.9 to 7.5)5.65 (4.56 to 6.43)6.1 (5.56 to 6.85)5.9 (4.73 to 6.79)9.8 (5.7 to 10.2)
WBC (1000/cubic mm)- 565.41 (4.6 to 7.1)6.76 (5.5 to 7.69)6.45 (5.34 to 8.39)5.44 (4.98 to 6.44)6.1 (5.6 to 7.5)5.9 (4.72 to 6.9)10.1 (9.9 to 11.8)
WBC (1000/cubic mm)- 1126.23 (5.1 to 6.7)6.39 (5.71 to 7.7)6.67 (5.44 to 7.98)5.4 (4.34 to 6.21)5.85 (5.09 to 6.7)6 (5.05 to 7.78)9.7 (8.9 to 10.1)
WBC (1000/cubic mm)- 1685.81 (4.61 to 7.1)5.51 (5.2 to 5.96)6.03 (5.25 to 7.6)5.28 (4.6 to 7.33)5.87 (4.71 to 7.01)5.7 (4.7 to 7.47)8.9 (8.7 to 10.9)
WBC (1000/cubic mm)- 2246.5 (4.47 to 6.8)5.93 (5.17 to 6.7)6.35 (4.88 to 7.52)5.3 (4.32 to 6)6 (5.2 to 6.6)5.4 (4.42 to 7.62)8.8 (7.2 to 11.3)
WBC (1000/cubic mm)- 2806.26 (5.3 to 7.18)6.59 (5.6 to 7.21)7 (5.13 to 7.5)5.56 (4.9 to 6.3)6.4 (5 to 7.3)5.8 (4.55 to 6.83)8.7 (7.2 to 10.2)
WBC (1000/cubic mm)- 3365.39 (4.3 to 7.57)6 (4.95 to 6.84)7.04 (5.74 to 8.4)5.43 (4.3 to 6.1)5.76 (5.37 to 6.39)5.49 (4.7 to 6.13)8.8 (8.6 to 12.1)
WBC (1000/cubic mm)- 3925.43 (4.4 to 6.9)5.9 (5.53 to 7.03)6.6 (5.29 to 7.31)5.08 (4.4 to 5.93)6.13 (5.2 to 7.5)5.6 (4.9 to 6.35)9.5 (8.5 to 9.9)
WBC (1000/cubic mm)- 4485.66 (4.6 to 6.6)6.26 (5.35 to 7.3)6 (5.23 to 8.22)5.45 (4.66 to 6.71)6.7 (4.45 to 7.1)5.7 (4.46 to 7)8.6 (8.5 to 10.6)
WBC (1000/cubic mm)- 5045.67 (4.51 to 6.65)6.3 (5.32 to 7.28)6.32 (5.2 to 8.91)5.55 (4.4 to 6.16)6.16 (5.51 to 6.7)5.05 (4 to 6.2)8.7 (8.2 to 11.9)
WBC (1000/cubic mm)- 7287.12 (7.12 to 7.12)6.6 (5 to 7.39)7.02 (5.52 to 56.95)4.8 (3.86 to 6)6.6 (6.15 to 7)6.18 (5.8 to 7.08)9.3 (9.3 to 9.3)
Platelets (1000/cubic mm)- Screening260 (234.9 to 295.1)251 (233.6 to 265)271 (228 to 328.3)273 (209.8 to 332)244.5 (214.5 to 289.5)240.1 (223.1 to 276)315 (246 to 334)
Platelets (1000/cubic mm)- 0/Enrollment254.9 (229.1 to 291.1)239 (224 to 274)254 (219 to 317)270 (207.95 to 313.5)247 (210.5 to 281.75)244.5 (221 to 275)283 (249 to 294)
Platelets (1000/cubic mm)- 56262.65 (235 to 278.7)255 (244 to 273)275.5 (238.5 to 346.1)283 (201 to 309)246 (218 to 293)246 (217 to 272.4)326 (284 to 337)
Platelets (1000/cubic mm)- 112244.45 (221 to 276)250 (231 to 268)284.5 (252.5 to 337.65)267 (196 to 303)252.8 (204 to 283)261.5 (209.55 to 286.8)316 (279 to 338)
Platelets (1000/cubic mm)- 168255.5 (234.65 to 269.05)255.5 (229 to 282)278.5 (242 to 311)271 (202.2 to 319.5)240.5 (203 to 299)257 (205.7 to 280)303 (302 to 328)
Platelets (1000/cubic mm)- 224264 (227.5 to 277.95)252 (228 to 277)283 (250.5 to 348.5)252 (198 to 324)234 (195 to 303)256.5 (205.15 to 281.1)341 (288 to 350)
Platelets (1000/cubic mm)- 280252.9 (229.6 to 303)249 (221 to 278)278 (222 to 338)250 (195 to 333)254.45 (215 to 287)257 (209 to 303.3)284.5 (243 to 326)
Platelets (1000/cubic mm)- 336242 (210 to 275)246 (217 to 277)270.5 (246 to 314)256 (193 to 348)238.5 (200 to 293.15)233 (206.3 to 259)310 (286 to 324)
Platelets (1000/cubic mm)- 392255.85 (234.6 to 282)255.5 (237 to 283)265 (244 to 311)251 (181 to 332)252 (213 to 294)250 (210.5 to 279.1)319 (283 to 321)
Platelets (1000/cubic mm)- 448249 (241 to 276.8)243.5 (233 to 272.5)264 (223.5 to 306)260 (212 to 300)254.4 (188 to 308)255 (214.7 to 296)336 (293 to 346)
Platelets (1000/cubic mm)- 504271.35 (244.5 to 289.6)252.65 (234.75 to 285)257.5 (246 to 338)268.5 (210.05 to 296)248.5 (193.5 to 280.5)251 (208.2 to 284)323 (251 to 325)
Platelets (1000/cubic mm)- 728283.2 (283.2 to 283.2)278 (210.4 to 297)250 (208 to 283)233 (191 to 249)263.5 (243.95 to 295.5)302 (273.5 to 382.5)327 (327 to 327)
PrimaryNumber of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC).

The number (percentage) of participants with lab grade \>= 1 for alanine aminotransferase (ALT), creatinine, hemoglobin, lymphocyte count, neutrophil count, platelets, white blood cells (WBC) was summarized by arm

Time frame:
Measured during screening, Days 0, 56, 112, 168, 224, 280, 336, 392, 448, 504, 728
Reported as:
Count of participants · Participants
Number of Lab Grade >= 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC).
ParticipantsGroup 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: Placebo
WBC (1000/cubic mm)- Screening0000000
WBC (1000/cubic mm)- 0/Enrollment0100000
WBC (1000/cubic mm)- 560000000
WBC (1000/cubic mm)- 1120000000
WBC (1000/cubic mm)- 1680000000
WBC (1000/cubic mm)- 2240000000
WBC (1000/cubic mm)- 2800000000
WBC (1000/cubic mm)- 3360000000
WBC (1000/cubic mm)- 3920000000
WBC (1000/cubic mm)- 4480000000
WBC (1000/cubic mm)- 5040000000
WBC (1000/cubic mm)- 7280000000
Neutrophils (1000/cubic mm)- Screening0000000
Neutrophils (1000/cubic mm)- 0/Enrollment0100000
Neutrophils (1000/cubic mm)- 560000000
Neutrophils (1000/cubic mm)- 1120000000
Neutrophils (1000/cubic mm)- 1680000000
Neutrophils (1000/cubic mm)- 2240000000
Neutrophils (1000/cubic mm)- 2800000000
Neutrophils (1000/cubic mm)- 3361000000
Neutrophils (1000/cubic mm)- 3921000000
Neutrophils (1000/cubic mm)- 4480000000
Neutrophils (1000/cubic mm)- 5040000000
Neutrophils (1000/cubic mm)- 7280000000
Hemoglobin (g/dL)- Screening0000000
Hemoglobin (g/dL)- 0/Enrollment1000000
Hemoglobin (g/dL)- 560000000
Hemoglobin (g/dL)- 1121000000
Hemoglobin (g/dL)- 1680000000
Hemoglobin (g/dL)- 2240000000
Hemoglobin (g/dL)- 2801010000
Hemoglobin (g/dL)- 3361000000
Hemoglobin (g/dL)- 3920010000
Hemoglobin (g/dL)- 4481000000
Hemoglobin (g/dL)- 5041000000
Hemoglobin (g/dL)- 7280000000
Lymphocytes (1000/cubic mm)- Screening0000000
Lymphocytes (1000/cubic mm)- 0/Enrollment0000000
Lymphocytes (1000/cubic mm)- 560000000
Lymphocytes (1000/cubic mm)- 1120000000
Lymphocytes (1000/cubic mm)- 1680000000
Lymphocytes (1000/cubic mm)- 2240000000
Lymphocytes (1000/cubic mm)- 2800000000
Lymphocytes (1000/cubic mm)- 3360000000
Lymphocytes (1000/cubic mm)- 3920000000
Lymphocytes (1000/cubic mm)- 4480000000
Lymphocytes (1000/cubic mm)- 5040000000
Lymphocytes (1000/cubic mm)- 7280000000
Platelets (1000/cubic mm)- Screening0000000
Platelets (1000/cubic mm)- 0/Enrollment0000000
Platelets (1000/cubic mm)- 560000000
Platelets (1000/cubic mm)- 1120000000
Platelets (1000/cubic mm)- 1680000000
Platelets (1000/cubic mm)- 2240000000
Platelets (1000/cubic mm)- 2800000000
Platelets (1000/cubic mm)- 3360000000
Platelets (1000/cubic mm)- 3920000000
Platelets (1000/cubic mm)- 4480001000
Platelets (1000/cubic mm)- 5040000000
Platelets (1000/cubic mm)- 7280000000
ALT (SGPT) (U/L)- Screening0000000
ALT (SGPT) (U/L)- 0/Enrollment0000110
ALT (SGPT) (U/L)- 560020001
ALT (SGPT) (U/L)- 1120010211
ALT (SGPT) (U/L)- 1681111111
ALT (SGPT) (U/L)- 2241000101
ALT (SGPT) (U/L)- 2801002110
ALT (SGPT) (U/L)- 3360001011
ALT (SGPT) (U/L)- 3923000001
ALT (SGPT) (U/L)- 4480000101
ALT (SGPT) (U/L)- 5040100001
ALT (SGPT) (U/L)- 7280000000
Creatinine (mg/dL)- Screening0000000
Creatinine (mg/dL)- 0/Enrollment1001000
Creatinine (mg/dL)- 560000000
Creatinine (mg/dL)- 1120011000
Creatinine (mg/dL)- 1680002010
Creatinine (mg/dL)- 2240011100
Creatinine (mg/dL)- 2800010100
Creatinine (mg/dL)- 3360002000
Creatinine (mg/dL)- 3920002300
Creatinine (mg/dL)- 4480001000
Creatinine (mg/dL)- 5040101000
Creatinine (mg/dL)- 7280000000
PrimaryVRC07523LS Serum Concentrations

VRC07523LS serum concentrations measured in healthy human subjects after up to five administrations of the study product via the IV, SC or IM routes at various doses. Serum concentrations between the first and second study product administrations (Target Visit Day 0-112) were measured using ELISA assay in all enrolled participants. Serum concentrations after the second study product administrations (Target Visit Day 168-784) were measured using BAMA (LUMINEX) assay in a subset of participants enrolled in each treatment group and all particiants in plocebo group. serum concentrations below the lower limit of quantification (LLoQ) were replaced by half the LLoQ. Thus, concentrations below the LLoQ when measured by the ELISA assay were replaced by 0.5 ug/ml and concentrations below the LLoQ when measured by the BAMA assay were replaced by 0.02285 ug/ml.

Time frame:
Target Visit Days 0, 3, 6, 28, 56, 84, 112, 168, 224, 280, 336, 392, 448, 504, 560, 616, 672, 728, 784 (i.e., visit numbers 2 through 20)
Reported as:
Median · ug/ml
VRC07523LS Serum Concentrations
ug/mlGroup 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: Placebo
IDVRC07-523LS (Day-000)0.5 (0.5 to 0.5)0.5 (0.5 to 0.5)0.5 (0.5 to 0.5)0.5 (0.5 to 0.5)0.5 (0.5 to 0.5)0.5 (0.5 to 0.5)0.5 (0.5 to 0.5)
IDVRC07-523LS (Day-003)43.13 (38.57 to 52.81)80.7 (73.52 to 101.15)332.57 (260 to 455.77)11.06 (7.95 to 15.28)17.81 (14.57 to 26.49)16.71 (15.16 to 19.14)0.5 (0.5 to 0.5)
IDVRC07-523LS (Day-006)27.71 (23.7 to 33.64)59.05 (49.91 to 71.34)224 (200.96 to 261.88)11.04 (8.26 to 13.21)22.22 (18.81 to 26.26)16.03 (13.89 to 17.81)0.5 (0.5 to 0.5)
IDVRC07-523LS (Day-028)14.56 (13.48 to 17.86)27.86 (25.92 to 36.53)125.17 (110.6 to 132.2)6.79 (5.63 to 8.36)13.37 (11.89 to 17.65)10.03 (8.91 to 11.87)0.5 (0.5 to 0.5)
IDVRC07-523LS (Day-056)10.67 (8.26 to 12.76)17.08 (15.32 to 21.55)68.97 (59.45 to 75.21)5.02 (3.81 to 5.7)7.63 (6.57 to 10.43)6.27 (5.72 to 7.39)0.5 (0.5 to 0.5)
IDVRC07-523LS (Day-084)5.43 (4.69 to 6.9)12.19 (10.33 to 14.17)45.27 (36.41 to 52.23)2.99 (0.86 to 4.12)5.9 (4.89 to 7.23)4.29 (3.48 to 5.33)0.5 (0.5 to 0.5)
IDVRC07-523LS (Day-112)4.08 (3.09 to 4.84)6.51 (5.33 to 7.59)26.83 (22.83 to 30.69)0.5 (0.5 to 2.14)3.95 (2.72 to 4.58)2.98 (1.88 to 3.53)0.5 (0.5 to 0.5)
IDVRC07-523LS (Day-168)13.14 (8.75 to 14.82)22.46 (19.66 to 24.95)98.34 (93.59 to 111.17)5.77 (4.19 to 6.56)10.99 (10.15 to 12.2)8.09 (6.07 to 8.74)0.02 (0.02 to 0.02)
IDVRC07-523LS (Day-224)5.55 (5.12 to 7.08)9.83 (8.89 to 11.74)36.11 (29.29 to 49.15)2.31 (1.11 to 3.17)5.95 (4.95 to 7.17)3.53 (2.41 to 4.52)0.02 (0.02 to 0.02)
IDVRC07-523LS (Day-280)12.17 (11.3 to 14.1)25.77 (20.13 to 27.8)93.35 (81.62 to 100.24)7.52 (3.42 to 8.66)13.65 (10.92 to 17.55)7.79 (5.88 to 10.33)0.02 (0.02 to 0.02)
IDVRC07-523LS (Day-336)5.5 (3.8 to 6.52)11.15 (7.74 to 12.77)38.01 (25.6 to 48.67)2.16 (1.49 to 3.2)6.39 (4.86 to 8.61)3.62 (2.82 to 4.01)0.02 (0.02 to 0.02)
IDVRC07-523LS (Day-392)13.31 (10.04 to 14.6)25.88 (22.09 to 30.52)98.93 (86.92 to 113.48)6.12 (3.94 to 8.47)12.76 (11.08 to 15.29)8.13 (6.66 to 9.47)0.02 (0.02 to 0.02)
IDVRC07-523LS (Day-448)5.6 (4.24 to 6.81)10.29 (9.04 to 15.12)40.22 (36.47 to 46.45)2.71 (2 to 4.39)6.06 (5.28 to 6.88)3.59 (3.23 to 4.26)0.02 (0.02 to 0.02)
IDVRC07-523LS (Day-504)14.18 (8.37 to 14.92)23.4 (20.28 to 28.7)98.2 (93.78 to 106.21)6.11 (4.77 to 8.11)13.22 (10.63 to 15.47)7.61 (6.58 to 8.92)0.02 (0.02 to 0.02)
IDVRC07-523LS (Day-560)5.08 (3.62 to 6.69)10.67 (9.21 to 15.27)41.17 (32.3 to 49.84)1.65 (1.42 to 3.68)7.17 (6.18 to 8.09)3.92 (3.56 to 4.32)0.02 (0.02 to 0.02)
IDVRC07-523LS (Day-616)2.7 (2.36 to 3.68)5.74 (4.59 to 6.72)20.78 (16.32 to 27.46)1.52 (0.58 to 1.96)3.63 (2.8 to 3.83)1.36 (0.89 to 1.69)—
IDVRC07-523LS (Day-672)1.14 (0.95 to 1.18)2.81 (1.67 to 3.63)10.68 (9.02 to 11.7)0.78 (0.61 to 1.45)1.29 (0.91 to 1.52)1.25 (0.95 to 1.56)—
IDVRC07-523LS (Day-728)0.47 (0.33 to 0.62)1.68 (0.59 to 2.27)5.87 (3.11 to 5.94)0.45 (0.45 to 0.85)0.74 (0.69 to 0.83)0.44 (0.33 to 0.47)0.02 (0.02 to 0.02)
IDVRC07-523LS (Day-784)0.51 (0.26 to 0.54)0.94 (0.72 to 1.09)2.17 (1.76 to 3.01)0.17 (0.1 to 0.33)0.36 (0.34 to 0.52)0.27 (0.2 to 0.29)0.02 (0.02 to 0.02)
SecondaryOccurrence of Antidrug Antibodies (ADA)

Antidrug antibodies (ADA) are most typically detected and characterized using a tiered testing strategy. In Tier I, a sensitive binding assay is used to determine if samples may have ADA present. In Tier II, the response is confirmed, typically by establishing the specificity of the response by competition with free drug. In Tier III, the response is characterized, typically with a neutralization reduction assay and/or a titering assay.

Time frame:
Day 0, 6, 112, 224, 448
Reported as:
Count of participants · Participants
Occurrence of Antidrug Antibodies (ADA)
ParticipantsGroup 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: Placebo
0 - Tier I2202010
0 - Tier II00—0—0—
112 - Tier I——0—0——
224 - Tier I0001000
224 - Tier II———1———
224 - Tier III———0———
448 - Tier I0100000
448 - Tier II—0—————
6 - Tier I—0—————
SecondaryMagnitude and Breadth of Neutralizing Antibody Responses Against Autologous Viral Isolates as Assessed by Area Under the Magnitude-breadth Curves 8, 72, 88 Weeks After the First Study Product Administration.

Magnitude-breadth characterize the magnitude (ID50 or ID80 titers) and breadth (number of virus isolates) of each individual serum sample assayed against a panel of virus isolates. MB curves show, for each possible magnitude threshold, the fraction of assays with magnitudes greater than this threshold. The area under the magnitude-breadth curve (AUC-MB) is calculated as the average of the log10-based ID50 or ID80 titers over the panel of isolates. Isolates includes: H703_0646_051sN, H703_1471_190s, H703_1750_140Es, H704_0726_080sN, H704_1535_030sN, H704_2544_140eN01, PVO.4.

Time frame:
Weeks 8, 72, and 88 following the first study product administration
Reported as:
Median · log10(titer)
Magnitude and Breadth of Neutralizing Antibody Responses Against Autologous Viral Isolates as Assessed by Area Under the Magnitude-breadth Curves 8, 72, 88 Weeks After the First Study Product Administration.
log10(titer)Group 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: Vaccine
ID50 (Week-08)1.56 (1.44 to 1.56)1.89 (1.74 to 2)2.46 (2.38 to 2.54)1.34 (1.23 to 1.54)1.54 (1.4 to 1.55)1.39 (1.26 to 1.45)
ID50 (Week-72)1.62 (1.57 to 1.81)2.03 (1.79 to 2.12)2.6 (2.5 to 2.67)1.36 (1.25 to 1.55)1.6 (1.48 to 1.71)1.49 (1.42 to 1.57)
ID50 (Week-88)0.98 (0.96 to 1.11)1.4 (1.26 to 1.4)1.93 (1.85 to 2.07)0.8 (0.7 to 0.94)0.97 (0.89 to 0.98)0.9 (0.8 to 0.96)
ID80 (Week-08)1.14 (1.04 to 1.19)1.37 (1.33 to 1.42)1.97 (1.89 to 2.03)0.93 (0.89 to 1.11)1.15 (1.03 to 1.2)1.01 (0.91 to 1.08)
ID80 (Week-72)1.27 (1.16 to 1.33)1.49 (1.35 to 1.55)2.14 (2.02 to 2.16)1 (0.88 to 1.12)1.21 (1.12 to 1.29)1.13 (1.02 to 1.18)
ID80 (Week-88)0.85 (0.77 to 0.88)0.91 (0.88 to 0.95)1.45 (1.41 to 1.55)0.7 (0.7 to 0.74)0.84 (0.8 to 0.84)0.75 (0.72 to 0.79)

Adverse events

Collected over The study Unsolicited AE reporting time frame is from study enrollment of a trial participant to (and including) the Week 112 visit (v20.0). The Solicited AE assessment were collected through 3 full days after each vaccination (vaccinations were given at weeks 0, 16, 32, 48 and 64).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Vaccine0/19 (0%)1/19 (5.3%)14/19 (73.7%)
Group 2: Vaccine0/19 (0%)1/19 (5.3%)16/19 (84.2%)
Group 3: Vaccine0/21 (0%)0/21 (0%)14/21 (66.7%)
Group 4: Vaccine0/21 (0%)1/21 (4.8%)18/21 (85.7%)
Group 5: Vaccine0/20 (0%)0/20 (0%)16/20 (80%)
Group 6: Vaccine0/21 (0%)0/21 (0%)17/21 (81%)
Group 7: Placebo0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventGroup 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: Placebo
Any Event in SOCInfections and infestations0/191/190/210/210/200/210/3
Staphylococcal infectionInfections and infestations0/191/190/210/210/200/210/3
Any Event in SOCRenal and urinary disorders1/190/190/210/210/200/210/3
Calculus urinaryRenal and urinary disorders1/190/190/210/210/200/210/3
Any Event in SOCGeneral disorders0/190/190/211/210/200/210/3
PyrexiaGeneral disorders0/190/190/211/210/200/210/3
Most frequent other events
Showing 10 of 191
Most frequent other events
EventGroup 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: Placebo
Any Event in SOCInfections and infestations9/1910/1911/219/2110/2012/213/3
Upper respiratory tract infectionInfections and infestations1/195/197/213/214/206/213/3
Any Event in SOCInvestigations4/193/198/219/215/205/212/3
Alanine aminotransferase increasedInvestigations3/191/193/213/212/202/212/3
Any Event in SOCMusculoskeletal and connective tissue disorders1/194/191/216/214/202/212/3
Any Event in SOCGastrointestinal disorders1/197/195/212/216/203/211/3
Any Event in SOCEye disorders0/190/190/210/211/200/211/3
Eczema eyelidsEye disorders0/190/190/210/210/200/211/3
DiarrhoeaGastrointestinal disorders1/191/190/210/210/200/211/3
Fungal infectionInfections and infestations0/190/190/210/210/200/211/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: PlaceboTotal
Median30 (18 to 50)30 (18 to 48)23 (19 to 50)29 (20 to 49)27 (21 to 37)27 (19 to 43)31 (24 to 35)28 (18 to 50)
Age, Customized
Age, Customized(Participants)Group 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: PlaceboTotal
Less than 18 years00000000
18 - 20 years434102014
21 - 30 years6711111713166
31 - 40 years674333228
41 - 50 years322603016
Above 50 years00000000
Unknown or Not Reported00000000
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: PlaceboTotal
Female14811151311375
Male511106710049
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: PlaceboTotal
Hispanic or Latino035202012
Not Hispanic or Latino1916161920193112
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: PlaceboTotal
American Indian or Alaska Native00000000
Asian01301106
Native Hawaiian or Other Pacific Islander00000000
Black or African American542566028
White121013101112371
More than one race221321011
Unknown or Not Reported02230108
Region of Enrollment
Region of Enrollment(Participants)Group 1: VaccineGroup 2: VaccineGroup 3: VaccineGroup 4: VaccineGroup 5: VaccineGroup 6: VaccineGroup 7: PlaceboTotal
USA1919212120213124
08

Study locations

7 sites
  • Alabama CRS
    Birmingham, Alabama 35294, United States
  • The Ponce de Leon Center CRS
    Atlanta, Georgia 30308-2012, United States
  • Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
    Boston, Massachusetts 02115-6110, United States
  • Fenway Health (FH) CRS
    Boston, Massachusetts 02215-4302, United States
  • Columbia P&S CRS
    New York, New York 10032-3732, United States
  • Chapel Hill CRS
    Chapel Hill, North Carolina 27599, United States
  • Lausanne Vaccine and Immunotherapy Center CRS
    Lausanne, Vaud 1011, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Dec 2020, 33 months.

Results were first posted in Mar 2022, 1 year 3 months after primary completion.

Of 91 non-industry phase 1 interventional studies under HIV Infections, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's 33 months is above that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2017
First posted
Dec 29, 2017
StartActual
Feb 28, 2018
Primary completionActual
Dec 7, 2020
CompletionActual
Dec 7, 2020
Results first posted
Mar 21, 2022
Last update
Apr 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03387150
Responsible party
Sponsor
First posted
Dec 29, 2017
Start date
Feb 28, 2018
Primary completion
Dec 7, 2020
Completion
Dec 7, 2020
Results posted
Mar 21, 2022
Last update
Apr 5, 2023

Study contacts

Stephen Walsh
study chair · Brigham and Women's Hospital
Cynthia Gay
study chair · University of North Carolina, Chapel Hill

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VRC07-523LS

Start the discussion